Mandana Kamgar

9PUBLICATIONS

56CO-AUTHORS

Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Solid tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (9)

Sort by Publication Date:

|Sep 30, 2026

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.

|Aug 27, 2026

Allele-Specific Mechanisms Guide Salvage Therapy to Overcome Daraxonrasib Resistance in Pancreatic Cancer.

|Oct 24, 2025

Mutant and Wild-Type RAS Cross-talk and Stoichiometric Deficiencies Are Determinants of Sensitivity to Targeted Therapies in KRASG12R Pancreatic Ductal Adenocarcinoma.

Mandana Kamgar, G Aaron Hobbes, Raven Davidson

|May 21, 2024

Chemotherapy-free treatment targeting fusions and driver mutations in KRAS wild-type pancreatic ductal adenocarcinoma, a case series.

Maahum Mehdi, Aniko Szabo, Aditya Shreenivas

|Dec 23, 2023

Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.

Saryleine de Ortiz de Choudens, Alexis Visotcky, Anjishnu Banerjee

|Jun 10, 2022

Systemic Therapy of Metastatic Pancreatic Adenocarcinoma: Current Status, Challenges, and Opportunities.

Sakti Chakrabarti, Mandana Kamgar, Amit Mahipal

Pageof 2

Frequent Collaborators

Susan Tsai

Douglas B Evans

Juliannie Herrera

Raven Davidson

Aniko Szabo

Mohammed Aldakkak

G Aaron Hobbs

John F Langenheim

Daniel Dorbin

Y David Seo

Frequent Collaborators

Susan Tsai

Douglas B Evans

Juliannie Herrera

Raven Davidson